- $701.80m
- $461.67m
Brief: Sagimet Biosciences' Board Appointed Joseph Oriti As Interim Principal Financial Officer
U.S. STOCKS ON THE MOVE-Intel, American Express, Spirit Airlines
U.S. STOCKS ON THE MOVE-Estee Lauder, L3Harris Technologies, Booz Allen
U.S. STOCKS ON THE MOVE-American Express, Colgate-Palmolive, BowFlex
Sagimet Biosciences drops on stock offering
Brief: Sagimet Biosciences Announces Pricing Of Public Offering Of Series A Common Stock
Brief: Sagimet Biosciences Estimates Its Cash, Cash Equivalents, Short-Term Investments In Marketable Securities Were About $94.9 Million
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Sagimet Biosciences hits record high as liver disease drug meets interim trial goal
Sagimet Biosciences rises on mid-stage study data on fatty liver disease drug
Brief: Sagimet Biosciences Announces Positive Topline Results From Phase 2B Fascinate-2 Clinical Trial Of Denifanstat In Biopsy-Confirmed F2/F3 Nash
Sagimet's fatty liver disease drug shows promise in trial (updated)
Sagimet's fatty liver disease drug shows promise in trial
Brief: Sagimet Biosciences- Anthony Rimac Provided Notice Of His Intent To Step Down As CFO
Brief: Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide
U.S. STOCKS ON THE MOVE-Paypal, Bowlero, Dycom
Brief: Sagimet Biosciences Completes Enrollment For Late-Stage Trial For Treatment Of Recurrent Glioblastoma
Brief: Sagimet Biosciences Reports Second Quarter 2023 Financial Results And Provides Corporate Updates
Brief: Sagimet Biosciences Announces Closing Of Underwriters’ Option To Purchase Additional Shares Of Series A Common Stock In Connection With Its Upsized Initial Public Offering